16732-71-1

Usage

Uses

Used in Pharmaceutical Industry:
7-Bromoindole-2-carboxylic acid is used as a building block for the synthesis of various biologically active molecules, particularly in the development of potential pharmaceutical drugs. Its unique reactivity and the presence of the bromine atom allow for diverse chemical transformations, facilitating the creation of new drug candidates with improved therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 7-Bromoindole-2-carboxylic acid serves as a versatile intermediate for the preparation of other complex organic compounds. Its reactivity and functional group make it an essential component in the synthesis of a wide range of organic molecules, contributing to the advancement of organic chemistry and the development of new materials.

InChI:InChI=1/C9H6BrNO2/c10-6-3-1-2-5-4-7(9(12)13)11-8(5)6/h1-4,11H,(H,12,13)

Upstream product

• 18474-55-0 2-(2-bromo-phenylhydrazono)-propionic acid ethyl ester 
• 16732-69-7 ethyl 7-bromo-1H-indole-2-carboxylate 

Downstream Products

• 51417-51-7 7-bromo-1H-indole 
• 1217-60-3 7-phenylindole-2-carboxylic acid 
• 1169857-25-3 7-bromo-1H-indole-2-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Synthesis of 3,3-Dihalo-2-oxindoles from 2-Substituted Indoles via Halogenation–Decarboxylation/Desulfonamidation–Oxidation Process

A novel one-pot reaction which combines halogenation, decarboxylation/desulfonamidation with oxidation has been developed. Diverse valuable 3,3-dihalo-2-oxindole compounds can be produced rapidly and safely with isolated yields of up to 98% under mild conditions. (Figure presented.).

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

The first potent and selective non-imidazole human histamine H4 receptor antagonists

Following the discovery of the human histamine H4 receptor, a high throughput screen of our corporate compound collection identified compound 6 as a potential lead. Investigation of the SAR resulted in the discovery of novel compounds 10e and 10l, which are the first potent and selective histamine H4 receptor antagonists to be described.